IL-6 contributes to the suppression of T and NK cell anti-tumor activity in EGFR-mutant NSCLC

Authors

Sonia A. Patel, The University of Texas MD Anderson Cancer Center
Monique B. Nilsson, The University of Texas MD Anderson Cancer Center
Yan Yang, The University of Texas MD Anderson Cancer Center
XIaoxing Yu, The University of Texas MD Anderson Cancer Center
Fahao Zhang, The University of Texas MD Anderson Cancer Center
Alissa Poteete, The University of Texas MD Anderson Cancer Center
Xiaoyang Ren, The University of Texas MD Anderson Cancer Center
Xiuning Le, The University of Texas MD Anderson Cancer Center
Li Shen, The University of Texas MD Anderson Cancer Center
Jing Wang, The University of Texas MD Anderson Cancer Center
John Heymach, The University of Texas MD Anderson Cancer Center

Files

Abstract

View full abstract

DOI

https://doi.org/10.52519/00073

Publication Date

2022

Department

Head and Neck Oncology

Research Category

Unleashing the Immune System to Develop Therapeutic Strategies

Recommended Citation

Patel, Sonia A.; Nilsson, Monique B.; Yang, Yan; Yu, XIaoxing; Zhang, Fahao; Poteete, Alissa; Ren, Xiaoyang; Le, Xiuning; Shen, Li; Wang, Jing; and Heymach, John, "IL-6 contributes to the suppression of T and NK cell anti-tumor activity in EGFR-mutant NSCLC" (2022). Leading Edge of Cancer Research Symposium. 33.
doi:https://doi.org/10.52519/00073